Trinity Legacy Partners LLC grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 99.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,879 shares of the company's stock after buying an additional 31,382 shares during the period. Johnson & Johnson accounts for approximately 2.6% of Trinity Legacy Partners LLC's investment portfolio, making the stock its 7th largest position. Trinity Legacy Partners LLC's holdings in Johnson & Johnson were worth $10,428,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. Highline Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $47,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $49,000. Capital A Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $50,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $52,000. Hedge funds and other institutional investors own 69.55% of the company's stock.
Johnson & Johnson Stock Up 0.1%
Shares of JNJ traded up $0.1680 during midday trading on Friday, reaching $179.0980. The stock had a trading volume of 9,523,149 shares, compared to its average volume of 8,657,504. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The company's fifty day simple moving average is $163.48 and its two-hundred day simple moving average is $159.30. The company has a market cap of $431.33 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 2.28 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the business earned $2.82 EPS. The company's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.
Analysts Set New Price Targets
Several equities analysts have recently commented on the stock. Bank of America upped their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Barclays increased their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Guggenheim reiterated a "neutral" rating and set a $167.00 target price (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $176.29.
View Our Latest Research Report on JNJ
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access